SUBSCRIBE
SUBSCRIBE
News   Drug Development

Analyst: Roche May Drop Taspoglutide Diabetes Drug

June 28, 2010 | 
1 min read
IndyStar -- Roche Holding AG may drop development of the taspoglutide diabetes drug and return the rights to developer Ipsen SA because the treatment has too many side effects, Morgan Stanley analysts said.
Clinical research Phase II
Roche
MORE ON THIS TOPIC
Hand holding a lung shape symbol against a blue background. World tuberculosis day, world no tobacco day, lung cancer, pulmonary hypertension, pneumonia
Lung cancer
AstraZeneca’s ATR Inhibitor Fails to Improve Survival in Phase III Lung Cancer Trial
December 22, 2025
 · 
1 min read
 · 
Annalee Armstrong
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
 · 
1 min read
 · 
Annalee Armstrong
Digital overload and its impact on the human brain, showcasing fragmented thoughts, information overload. Abstract design art collage. Social media digital addiction, mental health, stress, anxiety
Business
BioSpace Editors’ Top 5 Biggest News Stories of the Year
December 22, 2025
 · 
10 min read
 · 
Annalee Armstrong
Balloon and missed bow spears arround . Target audience and marketing concept . This is a 3d render illustration .
Infectious disease
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
December 19, 2025
 · 
2 min read
 · 
Tristan Manalac